Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
21 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Poor glycaemic control tied to sarcopaenia in diabetics

23 May 2019

Poor glycaemic control appears to correlate with low muscle mass in patients with type 2 diabetes, reports a new study.

The study included 746 type 2 diabetes patients (mean age, 69.9±9.1 years) who were compared against 2,067 elderly general population controls. Sarcopaenia was defined as slow usual gait speed, low skeletal mass index or weak grip strength.

Of the diabetic participants, 7.0 percent (n=52) were diagnosed with sarcopaenia. Stratifying the participants according to glycated haemoglobin (HbA1c) showed a direct and linear correlation with sarcopaenia prevalence.

For instance, in those with HbA1c <6.5 percent, the corresponding prevalence rate was 2.5 percent. This rose to 7.3 percent, 7.5 percent and 10.0 percent in the HbA1c categories ≥6.5 percent to <7.0 percent percent, ≥7.0 percent to <8.0 percent and ≥8.0 percent, respectively (p=0.053).

Logistic regression analysis showed that positive correlation between HbA1c and sarcopaenia was independent of confounders such as age, sex, body mass index, exercise habit, insulin therapy, cardiovascular diseases, and duration of diabetes and retinopathy, among others.

The fully adjusted model, for example, showed that the likelihood of sarcopaenia rose progressively in participants with HbA1c ≥6.5 percent to <7.0 percent (odds ratio [OR], 4.30; 95 percent CI, 1.11–16.65; p=0.035), ≥7.0 percent to <8.0 percent (OR, 4.48; 1.24–16.17; p=0.022) and ≥8.0 percent (OR, 7.65; 1.95–30.00; p=0.003).

The link between sarcopaenia and glycaemic control remained significant even when HbA1c was taken as a continuous variable in the model adjusted for only basic confounders (OR, 1.29; 1.01–1.74; p=0.041).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
21 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.